Unanimous support follows studies showing 66%-83% effectiveness.
The panel of outside advisers for the Centers for Disease Control and Prevention (CDC) unanimously voted last week to recommend the use of Bavarian Nordic’s Jynneos vaccine for adults at risk of mpox, previously referred to as monkeypox.
The panel reviewed multiple studies that collectively showed a full dose of the Jynneos vaccine was 66-83 percent effective at preventing mpox with no severe adverse effects. They also recommended injecting the vaccine between the layers of the skin rather than below it, but also approved below-the-skin injection.
This recommendation makes Jynneos the preferred mpox vaccine, as opposed to the Emergent BioSolutions’ smallpox vaccine approved for mpox treatment last year. Though the smallpox vaccine was effective in limiting last year’s mpox outbreak in the United States, its use was significantly limited due to its more severe side effects.
As the Lord Leads, Pray with Us…
- For the CDC advisers as they review studies and provide recommendations to the agency.
- For Director Rochelle Walensky to seek God’s direction as she heads the CDC.
- For wisdom for FDA officials as they consider the approval of new treatments and therapies.
Sources: CNN, Reuters
